Context Therapeutics Inc.
CNTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.25 | 0.06 | -0.01 |
| FCF Yield | 8.06% | -8.69% | -8.00% | -10.58% |
| EV / EBITDA | 2.38 | 5.59 | 7.63 | -3.91 |
| Quality | ||||
| ROIC | -11.80% | -6.06% | -4.50% | -22.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.66 | 1.10 | 1.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 199.33% | -3.17% | 70.60% | -397.34% |
| Safety | ||||
| Net Debt / EBITDA | 9.45 | 16.14 | 21.87 | 4.52 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -53,045.31 | 0.00 | 0.00 | 0.00 |